Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Currency in USD	2025
Operating Income	-252.87 Million
Income Before Tax	-291.1 Million
Income Tax Expense	-51.68 Million
Net Income	-245.03 Million
Eps	-1.41
Epsdiluted	-1.41
Weighted Average Shs Out	174.26 Thousand
Weighted Average Shs Out Dil	174.26 Thousand
Research And Development Expenses	172.92 Million
Selling General And Administrative Expenses	731.74 Million
Depreciation And Amortization	102.32 Million
Interest Expense	70.27 Million
Interest Income	12.63 Million
Net Interest Income	-57.64 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	797.90 Million
Ebitda	-150.55 Million
Source	edgar
Ebit	-220.83 Million

Tempus AI, Inc. Annual Reports (10-K)